Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jan 29.

Published in final edited form as: Vaccine. 2017 Dec 15;36(5):758–764. doi: 10.1016/j.vaccine.2017.12.024

Table 2.

Unadjusted mean fold increase stratified by baseline HI titer against A/Texas/50/2012

	Baseline A/Texas/50/2012 (n = 29)			Baseline A/Texas/50/2012 (n = 95)			All (n = 124)
	HI titer < 40			HI titer ≥ 40
Antigens	MFI	95% CI	P value^a	MFI	95% CI	P value^a	MFI	95% CI	P value^a
A/Switzerland/9715293/2013	3.30	2.36 – 4.63	< 0.0001	3.28	2.73 – 3.95	< 0.0001	3.29	2.80 – 3.87	< 0.0001
A/Texas/50/2012	1.84	1.50 – 2.26	< 0.0001	1.36	1.25 – 1.48	< 0.0001	1.46	1.34 – 1.58	< 0.0001
A/Victoria/361/2011	1.61	1.33 – 1.95	0.0002	1.37	1.25 – 1.51	< 0.0001	1.43	1.31 – 1.56	< 0.0001
A/Wuhan/359/1995	1.15	0.97 – 1.37	0.44	1.24	1.13 – 1.35	< 0.0001	1.22	1.13 – 1.31	< 0.0001

Abbreviations: MFI=mean fold increase, CI=confidence interval

^a

Statistical significance calculated with ANOVA using Bonferroni’s method of adjusting for multiple comparisons.